Remdesivir

Remdesivir - Reduces the risk of death in severely sick patients by 62%

remdesivir treatment was associated with “significantly improved clinical recovery.

74.4% of patients who received treatment with remdesivir recovered by day 14 compared with 59% of patients who received standard care alone. 

Last week, the company announced the much-anticipated pricing for remdesivir, saying it would charge governments of developed countries $390 per vial.

That comes to a price of $2,340 per patient, considering the company expects most patients to require six vials during their care.

However, Gilead said it would charge $520 per vial for U.S. private insurance companies. Gilead faced some backlash for charging a higher price in the United States, but the company defended itself, saying that’s simply a factor of the U.S. health-care system. 

https://www.cnbc.com/2020/07/10/gilead-says-remdesivir-coronavirus-treatment-reduces-risk-of-death.html